移植物抗宿主病的细胞治疗:组织修复与免疫耐受的平衡之道
异基因造血细胞移植的成功取决于供者免疫系统对受者恶性与非恶性细胞活性之间的精细平衡。多种细胞类型可抑制同种反应性免疫细胞并在小鼠中预防致死性GVHD,其中间充质基质细胞及程度较轻的调节性T细胞已在人体中显示疗效。本文结合GVHD病理生理学讨论急性和慢性GVHD细胞治疗的最新进展。
要点
- 消除同种反应性可致疾病复发,而同种免疫反应失控将导致致死性GVHD。
- 间充质基质细胞已在人体中显示疗效,调节性T细胞疗效证据相对较少。
- 组织损伤在GVHD病理生理中具有重要意义,支持开发固有淋巴细胞等支持组织稳态与修复的细胞。
核心结论
- GVHD的理想细胞治疗应在抑制同种反应性免疫的同时不影响针对肿瘤细胞的同种反应性免疫应答。
- 间充质基质细胞及程度较轻的调节性T细胞已在人体中显示疗效,固有淋巴细胞等支持组织稳态与修复的细胞是研发方向。
研究设计与样本
- 综述,结合GVHD病理生理学讨论预防和治疗急性和慢性GVHD的细胞治疗最新进展。
主要发现
- 多种细胞类型可抑制同种反应性免疫细胞并在小鼠中预防致死性GVHD。
- 间充质基质细胞已在人体中显示疗效,调节性T细胞的疗效证据相对较少。
- 组织损伤在GVHD病理生理中的重要性为开发支持组织稳态和修复的细胞(如固有淋巴细胞)提供了依据。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The success of allogeneic hematopoietic cell transplantation depends heavily on the delicate balance between the activity of the donor immune system against malignant and nonmalignant cells of the recipient. Abrogation of alloreactivity will lead to disease relapse, whereas untamed allo-immune responses will lead to lethal graft-versus-host disease (GVHD). A number of cell types have been identified that can be used to suppress alloreactive immune cells and prevent lethal GVHD in mice. Of those, mesenchymal stromal cells and, to a lesser extent, regulatory T cells have demonstrated efficacy in humans. Ideally, cellular therapy for GVHD will not affect alloreactive immune responses against tumor cells. The importance of tissue damage in the pathophysiology of GVHD rationalizes the development of cells that support tissue homeostasis and repair, such as innate lymphoid cells. We discuss recent developments in the field of cellular therapy to prevent and treat acute and chronic GVHD, in the context of GVHD pathophysiology.
引用
- Voermans C, Hazenberg MD. Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance. Blood. 2020. PMID: 32525970. doi:10.1182/blood.2019000951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。